Nova Acta Leopoldina0

Stroke – Global challenges, local solutions

Published by Dietmar Schmitz, Hilmar Bading

Current Advances, Challenges, and Opportunities in Stroke Research, Management, and Care

Julius Valentin Emmrich, Samuel Knauss and Matthias Endres ML

Download Publication (PDF)

Publication Details

  • Publication Date 23.07.2021
  • Volume number 2021.2
  • ISSN 2699-8955
  • Count pages 17
  • Count Figures 7
  • Count Tables 3

Stroke is the second leading cause of death worldwide and a major cause of disability. It leads to a considerable loss of years of life and enormous social and economic costs. Diagnosis and treatment of stroke is thus an important field of research. Typical symptoms of stroke include sudden onset of unilateral weakness and numbness in the face and arm as well as altered speech. In ischaemic strokes, the arterial blood supply to the brain is interrupted by an embolism or thrombosis. Less frequently, strokes are caused by bleeding in the brain. Imaging techniques, especially computed tomography (CT), can reliably distinguish between an ischaemic stroke and a haemorrhage. CT scans with contrast medium can locate large vessel occlusions and identify brain tissue that can still be saved by restored blood flow. The treatment of an acute ischaemic stroke then focuses on the rapid reperfusion of the affected brain tissue. For this purpose, vascular occlusions are dissolved with medication or surgically removed. Further treatment in a specialised stroke unit and rehabilitation increase the patient's chances of survival and reduce permanent impairments. A stroke caused by bleeding is treated in hypertensive patients by lowering blood pressure to prevent the bleeding from expanding. In some cases, haemostatic drugs or surgery may also be useful. Recurrent strokes are best prevented by lifestyle changes along with control of high blood pressure, blood lipids, diabetes and smoking. Targeted interventions depend on the individual causes of the stroke. Possible interventions include blood-thinning medications, inhibiting blood clotting in atrial fibrillation, surgically restoring the patency of the carotid artery or inserting stents, and surgically closing an opening between the atria.

doi:10.34714/leopoldina_nal-live_0002_01000

A NAL-live article open for comments and discussion. More information

This article is open for online discussion and comments. To engage, click the link on the right.

The Leopoldina uses cookies

We use cookies on our website. Some of them are necessary (functional cookies), while others are not necessary but help us to improve our online offering and operate it economically.

You can consent to the use of non-essential cookies by clicking on the "Accept all" button or by clicking on individual settings and agreeing to them by clicking on "Accept selection".

You can access these settings at any time and deselect cookies at a later date.

Functional

These cookies are technically necessary in order to provide the following core functionalities of the website:

  • Display of the website
  • Anonymisation of IP addresses within log files
  • Status cookie consent
Comfort

In addition to necessary cookies, we also use cookies to make your use of the website more pleasant. If you accept these cookies, external media will be loaded without your further consent.

Tracking

With the help of statistics cookies, we can better customise the content and services of our website to your interests and needs. For statistics and analyses, we use the product Matomo for statistics and analyses.

External link warning

Die Nutzung dieses Teildienstes erfordert ihre Einwilligung in die Verarbeitung zusätzlicher personenbezogener Daten durch einen selbständigen Verantwortlichen: Matterport Inc., 352 E. Java Drive, Sunnyvale, CA 94089, USA. Es gelten folgende Datenschutzhinweise: https://matterport.com/de/node/44. Mit der Einwilligung durch Klick auf „Ok“ kann auch eine Übermittlung von personenbezogenen Daten in ein Land außerhalb der Europäischen Union erfolgen. Die Einwilligung ist freiwillig. Eine Ablehnung führt zu keinen Nachteilen. Eine erteilte Einwilligung kann jederzeit mit Wirkung für die Zukunft widerrufen werden.

Ich bin damit einverstanden, dass bei Nutzung dieses Teildienstes zusätzliche personenbezogene Daten verarbeitet werden. Dabei verarbeitete Datenkategorien: technische Verbindungsdaten des Serverzugriffs (IP-Adresse, Datum, Uhrzeit, abgefragte Seite, Browser-Informationen), Daten zur Erstellung von Nutzungsstatistiken und Daten über die Nutzung der Website sowie die Protokollierung von Klicks auf einzelne Elemente. Zweck der Verarbeitung: Auslieferung von Inhalten, die von Dritten bereitgestellt werden. Rechtsgrundlage für die Verarbeitung: Ihre Einwilligung nach Art. 6 (1) a DSGVO, Art. 49 DSGVO. Verantwortlicher für die Datenverarbeitung Matterport Inc., 352 E. Java Drive, Sunnyvale, CA 94089, USA. Es gilt die Datenschutzerklärung von Matterport Inc.: https://matterport.com/de/node/44.

Visit page ▸